Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Cell Culture Market analysis
Part of: Cell Culture Market (Global)

The China Cell Culture Market was valued at $2118.5 Million in 2026 and projected to reach to $4203.8 Million by 2031, representing a compound annual growth rate of 14.7%. China's cell culture market is poised for exceptional growth through 2031, driven by government initiatives supporting domestic biopharmaceutical innovation and manufacturing capabilities.

China Cell Culture Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Cell Culture Market Trends and Insights

  • This accelerated growth in China significantly outpaces the global average of 12.1%, driven by increasing biopharmaceutical R&D investments, rising demand for biologics manufacturing, and government support for biotechnology innovation.
  • China's cell culture sector benefits from expanding capacity in contract manufacturing organizations (CMOs) and contract research organizations (CROs), alongside growing adoption of advanced culture technologies. The cell culture market in China is propelled by several key factors including the nation's emergence as a global manufacturing hub, substantial government funding for life sciences, and rising prevalence of chronic diseases requiring biologic therapies.
  • China's regulatory environment has become increasingly favorable for cell-based therapies and regenerative medicine applications.
  • The forecast period (2026–2031) will likely see China consolidate its position as a critical player in global cell culture supply chains, with particular strength in vaccine production, monoclonal antibody manufacturing, and stem cell research applications..

Key Market Statistics

  • CAGR (2026-2031) 14.7% CAGR
  • Market Size, 2026 ~USD 2118.5 Million
  • Forecast, 2031 ~USD 4203.8 Million
  • Country China

China Cell Culture Market Overview

Fastest Growing Market Globally :

China's cell culture market is expanding at 14.7% CAGR, significantly outpacing the global average of 12.1%, making it the most dynamic market for cell culture technologies and services in the world.

Biopharmaceutical R&D Acceleration :

Substantial government investments and private sector funding in biopharmaceutical research and development are driving demand for advanced cell culture systems and infrastructure across Chinese pharmaceutical companies.

Biologics Manufacturing Boom :

Rising demand for biologics production, including monoclonal antibodies and recombinant proteins, is creating unprecedented opportunities for cell culture media, equipment, and services in China's manufacturing sector.

Projected Market Doubling :

The market is expected to nearly double from USD 2,118.5 million in 2026 to USD 4,203.8 million by 2031, reflecting China's strategic positioning as a global biomanufacturing hub.

China Cell Culture Market Dynamics

  • The country's commitment to reducing reliance on imported biologics, combined with substantial R&D investments from both state-owned and private enterprises, is creating robust demand for cell culture technologies, media formulations, and bioreactor systems. The expansion is further supported by China's emergence as a contract manufacturing organization (CMO) hub for global pharmaceutical companies.
  • Increasing collaborations between Chinese biotech firms and international partners, coupled with improving regulatory frameworks and quality standards, will accelerate market penetration.
  • By 2031, China is expected to become a dominant force in cell culture innovation and manufacturing, attracting significant capital investment and talent..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • China's cell culture market will nearly double from USD 2,118.5M (2026) to USD 4,203.8M (2031) at a 14.7% CAGR, outpacing global growth.
    • China's biopharmaceutical manufacturing expansion and government biotech investments are primary drivers of cell culture market acceleration.
    • China dominates vaccine and monoclonal antibody production within cell culture, positioning the country as a critical global supply chain node.
    • Advanced culture technologies and regenerative medicine applications are emerging high-growth segments within China's cell culture market.

    Cell Culture Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment TISSUE ENGINEERING & REGENERATIVE MEDICINE (Application)
    Forecast Period 2026–2031
    Growth Rate CAGR of 12.1% from 2026 to 2031
    Largest Segment PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 33 (2026)
    Revenue Forecast (Billions) ~USD 58.42 (2031)
    Segments Covered Product, Type, Application, End User

    China Cell Culture Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Consumables
    • Equipment

    By Type

    • Adult Bovine Sera
    • Antibiotics/Antimycotics
    • Attachment & Matrix Factors
    • Autoclaves
    • Balanced Salt Solutions
    • Bhk Media
    • Bioreactors
    • Biosafety Cabinets
    • Buffers & Chemicals
    • Carbon Dioxide Incubators
    • Cell & Gene Therapy
    • Cell Counters
    • Cell Dissociation Reagents
    • Cell Factory Systems/Cell Stacks
    • Centrifuges
    • Chemically-Defined Media
    • Cho Media
    • Classical Media & Salts
    • Contamination Detection Kits
    • Cryoprotective Reagents
    • Cryostorage Systems
    • Fetal Bovine Sera
    • Filtration Systems
    • Flasks
    • Growth Factors
    • Hek 293 Media
    • Media
    • Microscopes
    • Monoclonal Antibody Production
    • Multiwell Plates
    • Other Animal Sera
    • Other Consumables & Accessories
    • Other Media
    • Other Reagents
    • Other Serum-Free Media
    • Other Supporting Equipment
    • Other Therapeutic Protein Production
    • Other Tissue Engineering & Regenerative Medicine Applications
    • Petri Dishes
    • Reagents
    • Refrigerators & Freezers
    • Roller/Roux Bottles
    • Sera
    • Sera, Media, And Reagents
    • Serum-Free Media
    • Serum-Free Stem Cell Media
    • Specialty Media
    • Stem Cell Culture Media
    • Storage Equipment
    • Supplements
    • Supporting Equipment
    • Vaccine Production
    • Vero Cell Media
    • Vessels

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Screening & Development
    • Other Applications
    • Tissue Engineering & Regenerative Medicine

    By End User

    • Academic & Research Institutes
    • Hospitals & Diagnostic Laboratories
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    CHINA: CELL CULTURE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES328.7355.7388.5427.1473.6529.3595.6674.611.7
    HOSPITALS & DIAGNOSTIC LABORATORIES433.2473.7523.1581.6652.4738840.9964.813
    OTHER END USERS206.1227.3253.2283.9321.3366.7421.6488.214
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES13361489.61677.71902.52176.52511.429193416.215.3
    TOTAL2304.12546.22842.53195.23623.74145.44777.25543.814.3

    Target Audience

    • Biopharmaceutical Companies : Chinese and international biotech firms need market intelligence to optimize R&D investments, identify manufacturing partners, and understand local demand drivers for cell culture products and services.
    • Cell Culture Suppliers & Manufacturers : Equipment, media, and reagent suppliers require detailed market segmentation and growth forecasts to prioritize product development, distribution strategies, and sales resource allocation in China's expanding market.
    • Contract Manufacturing Organizations (CMOs) : Chinese and global CMOs need competitive benchmarking data and market trends to assess capacity expansion opportunities, pricing strategies, and service differentiation in this rapidly growing manufacturing hub.
    • Investment & Private Equity Firms : Investors evaluating opportunities in Chinese biotech and life sciences require validated market data, growth projections, and sector analysis to make informed funding decisions and portfolio allocation choices.
    • Healthcare Policy & Government Bodies : Chinese government agencies and health authorities need market research to inform policy development, funding allocation, and strategic initiatives supporting domestic biopharmaceutical innovation and manufacturing capabilities.

    Key Companies in the China Cell Culture Market

    CompanyHQOwnershipStrongest segments
    PATHEON INCNetherlandsPrivate CompanyDrug product services (oral, sterile, packaging, lifecycle management),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small-molecule and biologics APIs),
    BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (culture media, VITEK, blood culture, ID/AST),Molecular and syndromic diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome),
    SIGMA-ALDRICH CORPORATIONUnited StatesPrivate CompanyChemicals, biochemicals, and analytical reagents,Cell culture media, critical raw materials, and bioprocess solutions,Filtration, water purification, and labware,
    HI-MEDIAFrancePublic CompanyIn-content native and integrated formats,Geo-marketing and location-based solutions,Managed campaign and data-driven services,
    REPLIGEN CORPORATIONUnited StatesPublic CompanyFiltration and cell retention (XCell ATF, KrosFlo, TangenX, ProConnex TFDF),Chromatography (OPUS columns, KRM systems, resins, ELISA kits),Process analytics and PAT (PATsmart suite, SoloVPE/FlowVPE, ZipChip, REBEL),
    QIAGEN NVNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease assays,Oncology and sexual & reproductive health assays,
    QUIDEL CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
    FLUOR CORPORATIONUnited StatesPublic CompanyEnergy Solutions,Urban Solutions,Mission Solutions,
    TECHNICOLOR SAFrancePublic CompanyBroadband gateways and routers (fiber, xDSL, cable),Wi-Fi extenders, Wi-Fi XL, homeware and in-home networking,Video set-top boxes, dongles, smart media devices,
    EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents (clinical),Urinalysis test strips and analyzers,
    MAXCYTE, INCUnited StatesPublic CompanyExPERT Instruments (ATx, STx, GTx, VLx),Consumables (Processing Assemblies, Buffers, Accessories),Licensing and Technology Access,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences tools and genomic medicine,Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (tools, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid and process chromatography/filtration),Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing),Analytical and PAT solutions (BLI, cytometry screening, live-cell imaging, SPR, data analytics),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, connectors),Display glass substrates (LCD/OLED),Specialty materials and optics,
    FUJIFILM HOLDINGS CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display/touch panels, semiconductor and display materials, storage media, industrial equipment, fine chemicals),Business Innovation (office equipment, document solutions, graphic communications, industrial inkjet),
    BDUnited StatesPublic CompanyMedical Essentials (syringes, needles, vascular access, sharps, enteral),Connected Care (infusion pumps, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions),
    EPPENDORF SEGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
    LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian DS/DP platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs/bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
    GETINGESwedenPublic CompanyAcute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR equipment, anesthesia, OR integration, sterile supply management),Life Science (sterilization, biocontainment, bioprocess, labware cleaning, vivarium),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab (Services, Consumables, Software),Applied Markets (GC, MS, Spectroscopy, Vacuum, Remarketed),
    BIO-TECHNEUnited StatesPublic CompanyProtein Sciences (reagents and proteomic tools),Diagnostics products and controls,Genomics and spatial biology,

    PATHEON INC

    Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

    SIGMA-ALDRICH CORPORATION

    Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees, supplying research chemicals and biochemicals globally.

    HI-MEDIA

    HI-MEDIA is a French public company founded in 1996 with 29 employees that manufactures culture media and laboratory reagents for microbiology.

    REPLIGEN CORPORATION

    Repligen Corporation is a United States-based public company founded in 1981 with 2,000 employees providing bioprocessing solutions and chromatography products.

    QIAGEN NV

    QIAGEN NV is a Netherlands-based public company founded in 1984 with 5,500 employees specializing in molecular diagnostics and sample preparation technologies.

    QUIDEL CORPORATION

    Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees developing rapid diagnostic testing solutions.

    FLUOR CORPORATION

    Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees providing engineering, procurement, and construction services.

    TECHNICOLOR SA

    Technicolor SA is a France-based public company founded in 1985 with 1,552 employees offering media and entertainment technology services.

    EIKEN CHEMICAL CO., LTD.

    Eiken Chemical Co., Ltd. is a Japan-based public company founded in 1939 with 696 employees manufacturing diagnostic reagents and laboratory chemicals.

    MAXCYTE, INC

    MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical instruments globally.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating diversified businesses in life sciences, diagnostics, and environmental solutions.

    MERCK KGAA

    Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees providing pharmaceuticals, chemicals, and life science products and services.

    SARTORIUS AG

    Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees manufacturing laboratory and bioprocess equipment for the life sciences industry.

    CORNING INCORPORATED

    Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees producing specialty glass, ceramics, and optical products.

    FUJIFILM HOLDINGS CORPORATION

    Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating in imaging, information, and document solutions.

    BD

    BD is a United States-based public company founded in 1897 with 72,000 employees manufacturing medical devices, diagnostics, and life science tools.

    EPPENDORF SE

    Eppendorf SE is a Germany-based private company founded in 1945 with 4,358 employees manufacturing laboratory equipment and consumables for life sciences research.

    LONZA

    Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services and products.

    GETINGE

    Getinge is a Sweden-based public company founded in 1904 with 11,754 employees manufacturing medical devices and systems for healthcare and life sciences.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

    BIO-TECHNE

    Bio-Techne is a United States-based public company founded in 1976 with 3,100 employees providing protein reagents, antibodies, and analytical instruments for life sciences research.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for China (USD 2,118.5M in 2026) with verified 14.7% CAGR projections through 2031, enabling accurate business planning and investment decisions specific to this high-growth market.
    • Competitive Landscape Intelligence : Understand China's unique competitive dynamics, local player strategies, and market consolidation trends that differ significantly from global markets, providing strategic advantages for market entry or expansion.
    • Government Policy & Regulatory Insights : Access detailed analysis of Chinese government initiatives, subsidies, and regulatory frameworks driving cell culture adoption, essential for navigating compliance and identifying funding opportunities in this market.
    • Segment & Application Breakdown : Identify high-potential segments within China's market—including therapeutic development, vaccine production, and contract manufacturing—with specific growth rates and investment priorities for targeted business development.
    • Strategic Partnership Opportunities : Leverage comprehensive data on Chinese biopharmaceutical companies, CMOs, and research institutions to identify collaboration, acquisition, or distribution partnership opportunities in this rapidly expanding ecosystem.

    Frequently asked questions

    What is the projected size of China's cell culture market in 2031?

    China's cell culture market is forecast to reach USD 4,203.8 million by 2031, growing from USD 2,118.5 million in 2026.

    What is the CAGR for China's cell culture market?

    China's cell culture market is expected to grow at a compound annual growth rate of 14.7% between 2026 and 2031.

    Why is China's cell culture market growing faster than the global average?

    China's 14.7% CAGR exceeds the global 12.1% due to increased biopharmaceutical R&D, government biotech support, CMO/CRO expansion, and rising biologics demand.

    What are the primary applications driving China's cell culture market?

    Key applications in China include vaccine production, monoclonal antibody manufacturing, stem cell research, and regenerative medicine therapies.

    How does China's cell culture market compare to other Asia Pacific countries?

    China represents the largest and fastest-growing cell culture market in Asia Pacific, driven by manufacturing scale, regulatory reforms, and biotech investment intensity.

    RESEARCH METHODOLOGY

    This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell culture market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell culture market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration, American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), International Serum Industry Association (ISIA), Pharmaceutical Research and Manufacturers of America (PhRMA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), American Type Culture Collection (ATCC), and the Alliance for Regenerative Medicine (ARM); corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Cell Culture Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Cell Culture Market : Top-Down and Bottom-Up Approach

    Cell Culture Market Top Down and Bottom Up Approach

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Cell culture refers to the removal of cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.

    The scope of this report includes products such as equipment and consumables, such as media, sera, reagents, vessels, bioreactors, storage equipment, and other cell culture-supporting equipment that support the cell culture process.

    Key Stakeholders

    • Cell Culture Equipment and Reagents Manufacturers
    • Analytical and Life Science Instrumentation Companies
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Life Science Companies
    • Venture Capitalists and Investors
    • Government Organizations
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Hospitals and Diagnostic Laboratories
    • Cell Banks

    Report Objectives

    • To define, describe, and forecast the global cell culture market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell culture market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the cell culture market
    • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the cell culture market

    Available customizations:

    Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:

    Portfolio Analysis

    • Product Matrix, which gives a detailed comparison of the product portfolios of the top five companies.

    Regional Analysis

    • A further breakdown of the Rest of Europe cell culture market, by country
    • A further breakdown of the Rest of Asia Pacific cell culture market, by country
    • A further breakdown of the Rest of Latin America cell culture market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five).

    Get the Full Cell Culture Market Report

    Full forecast, segment splits, and company analysis for all Cell Culture Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status